A fter the occlusion of a nutritive blood vessel, muscle undergoes a continuum of molecular, cellular, and extracellular responses that determine the fate of the ischemic tissue. During the latter phase of tissue healing, the different processes involved in new vessel formation, including angiogenesis, take place and represent an integral component of tissue remodeling, which controls the extent of ischemic injury. Angiogenesis is a complex process requiring the coordinated regulation of many activating and inhibitory pathways in which vascular endothelial growth factor (VEGF)-mediated endothelial cell (EC) migration and proliferation play an important role. VEGF acts, at least in part, through interaction with its VEGF receptor 2, also known as kinase insert domain receptor (KDR) in human or fetal liver kinase 1 (Flk1) in murine. Although the signaling pathways downstream of VEGF-mediated KDR/Flk1 activation have been analyzed in detail, the precise complex biology of this receptor has yet to be defined.
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The X-box binding protein 1 (XBP1) exists as unspliced (XBP1u) and spliced (XBP1s) forms via the action of inositol-requiring enzyme 1α (IRE1α)-mediated unconventional splicing, in which XBP1u facilitates the recruitment of XBP1 mRNA cotranslationally.
1 In addition, XBP1s protein level is downregulated by XBP1u through proteasome-mediated degradation.
2 XBP1, a stress-inducible transcription factor, constitutes a key signal transducer in the endoplasmic reticulum (ER) stress response. The ER has emerged as a major site of cellular homeostasis, particularly for the unfolded protein response, which has been shown to play a major role in cancer and many other diseases. XBP1 has been identified as a target of ATF6, a major sensor and transducer protein on the ER membrane, leading to unconventional mRNA splicing and production of XBP1s, which can activate the unfolded protein response efficiently. 1 Alternatively, XBP1s can act independently of its role in the ER stress response and is, for example, able to interact with the Forkhead box O1 transcription factor, leading to its proteasome-mediated degradation without improving the ER folding capacity. + and Flk1 + cells. Furthermore, endothelium-specific deletion of XBP1 (XBP1ecko) abrogates both retinal vasculogenesis and postischemic angiogenesis in mice with surgically induced hind-limb ischemia. 4 In this pathological setting, it is noteworthy that whereas reconstitution of XBP1 via adenovirus-mediated XBP1s gene transfer improves foot perfusion in XBP1ecko animals, administration of VEGF-A is unable to restore tissue perfusion in ischemic legs of XBP1ecko animals, suggesting that functional XBP1 in ECs is essential for both basal and VEGF-A-induced tissue perfusion recovery in ischemic tissues. This striking observation suggests that XBP1 may be involved in additional molecular and cellular pathways governing postischemic revascularization. Tissue reperfusion after ischemia is controlled by arteriogenesis, the appearance of new arteriolar structures, and collateral growth, the development and remodeling of preexisting arteriolar anastomoses. Both are characterized by proliferation of smooth muscle cells and production of the extracellular matrix within the vascular wall. Interestingly, a decrease in smooth muscle cells is also observed in ischemic tissue of XBP1ecko animals, suggesting that XBP1 may be involved in an interaction between ECs and smooth muscle cells. It is also likely that XBP1 is involved in VEGF-independent effects. Indeed, the authors showed that conditioned medium from nontargeted lentivirus-treated ECs could rescue proliferation of XBP1 knockdown of ECs, suggesting that soluble factors secreted by ECs may control EC proliferation in the absence of VEGF.
Alternatively, it has been shown that cellular components of the inflammatory system play a critical role in this setting. 5 Hence, numerous studies have demonstrated the importance of lymphocyte and monocyte recruitment in stimulating vessel growth and remodeling in ischemic tissue, [6] [7] [8] [9] [10] [11] including Tie-2-positive myeloid cells. Indeed, the authors used Tie2Cre mouse to generate XBP1ecko animals, and it is conceivable that hematopoietic cells contribute to the XBP1-deficient phenotype. Of note, it was shown that transplantation of bone marrowderived cells isolated from XBP1ecko animals display reduced foot perfusion compared to transplantation of wild-type bone marrow-derived cells. These data suggest that XBP1 can directly or indirectly control bone marrow-derived inflammatory cell mobilization or recruitment to ischemic tissues and subsequently may affect postischemic revascularization.
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The IRE1α/XBP1 pathway is one of the multiple signal pathways activated by ER stress response. Interestingly, as revealed by this study, VEGF treatment does not activate other major sensor and transducer proteins on the ER membrane such as ATF6 and PERK. 12 However, knockdown of KDR by siRNAs abolished VEGF-induced IRE1α phosphorylation, XBP1 splicing, and expression of C/EBP homologous protein-10 (CHOP-10). CHOP-10 is expressed at low levels under physiological conditions but is strongly induced at the transcription level in response to IRE1, ATF6, and PERK.
12 CHOP-10 is a significant mediator of apoptosis, and it has recently been shown to control angiogenesis. Endothelial nitric oxide synthase (eNOS) mRNA and protein levels are significantly upregulated in CHOP-10-deficient human ECs, whereas overexpression of CHOP-10 inhibits basal transcriptional activation of the eNOS promoter. Interestingly, postischemic revascularization is increased in CHOP-10 −/− mice with surgically induced hind-limb ischemia, and this effect is fully blunted in CHOP-10/eNOS doubleknockout animals. 13 In this regard, it should be noted that overexpression of XBP1s increases AKT phosphorylation, whereas knockdown of XBP1 or IRE1α attenuates the VEGF-induced AKT phosphorylation. The phosphorylation of eNOS by AKT represents a major Ca 2+ -independent regulatory mechanism for the activation of eNOS.
14 Thus, it is plausible that the activation of eNOS signaling participates in the XBP1-induced increase in tissue perfusion. Hence, one cannot exclude the possibility that VEGF-induced IRE1α phosphorylation may activate the XBP1 proangiogenic pathway and the CHOP-10 angiostatic signaling. Hence, regulation of both XBP1 and CHOP-10 in the setting of ischemia may be part of an evolutionarily conserved mechanism that activates both proapoptotic and survival pathways to allow eukaryotic cells to adapt to pathological stress.
Finally, although the specific targets of XBP1s remain to be fully identified, the results of this very interesting study by Zeng et al highlight the concept that XBP1 can function in growth factor signal pathways, regulating angiogenesis and tissue perfusion, and may therefore be involved in other ischemic settings such as stroke or myocardial infarction. In support of this hypothesis, transient cerebral ischemia has been shown to activate XBP1 mRNA splicing, which protects cells from ischemia/reperfusion-induced damage. 15 Hence, XBP1 may serve as putative target for novel therapeutic strategies in patients with ischemic cardiovascular diseases. 
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Figure.
The X-box binding protein 1 (XBP1) games in angiogenesis. Vascular endothelial growth factor (VEGF)-A can activate XBP1 mRNA splicing through kinase insert domain receptor (KDR) interaction with unspliced XBP1 (XBP1u) and inositolrequiring enzyme 1α (IRE1α). The spliced XBP1 (XBP1s) regulates the Akt/GSK/β-catenin/E2F2 signal pathway, leading to endothelial cell proliferation. Knockdown of KDR abolishes the expression of C/ EBP homologous protein-10 (CHOP-10). CHOP-10 is expressed at low levels under physiological conditions but is strongly induced at the transcription level in response to major sensor and transducer proteins on the endoplasmic reticulum membrane such as IRE1, ATF6, and PERK. CHOP-10 is a transcription factor shown to inhibit the expression of the proangiogenic endothelial nitric oxide synthase (eNOS). XBP1 may also be involved in endothelial cell and smooth muscle cell interaction and likely in the control of the immunoinflammatory reaction, both of which may participate in the overall effect of XBP1 on postischemic revascularization. 
